Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast
Usnoflast is a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)
Usnoflast is a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)